0.2675USD-0.93%Mkt Cap: 9.35M USDP/E: —Last update: 2026-05-26
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operate…
Industry Peers
Diagnostics & Research166.94BUSDP/E 24.7
122.72BUSDP/E 33.6
44.05BUSDP/E 41.1
34.42BCHFP/E 37.9
33.46BUSDP/E 43.3
32.69BUSDP/E 25.5
28.46BUSD—
27.28BUSDP/E 20.3
Indicators:|
Key Statistics
Company
Market Cap9.35M USD
Enterprise Value477.91M USD
Revenue (TTM)507.36M USD
Gross Profit120.98M USD
Net Income (TTM)-68.63M USD
Revenue/Share14.73 USD
Last Price0.2675 USD
Fiscal Year EndSep 2025
MR QuarterMar 2026
Employees1.9K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISINUS45783Q1004
Valuation
P/E (Trailing)—
P/E (Forward)-5.49
PEG—
EV/EBITDA297.76
EV/Revenue0.94
P/S0.02
P/B0.12
EPS (TTM)-2.48
EPS (Forward)-0.05
52W Range
0.22002% of range3.320
52W High3.320 USD
52W Low0.2200 USD
Profitability
Gross Margin23.58%
Oper. Margin-16.41%
EBITDA Margin0.32%
Profit Margin-13.38%
ROE-50.45%
ROA-8.90%
Growth
Revenue Growth-5.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.46M USD
CapEx (TTM)16.61M USD
FCF Margin4.06%
FCF Yield220.62%
Net Debt468.34M USD
Net Debt/EBITDA291.80
Balance Sheet
Debt/Equity3.38
Current Ratio0.27
Quick Ratio0.14
Book Value/Sh2.210 USD
Cash/Share0.4350 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.250 USD
Target Range1.500 USD – 5.000 USD
# Analysts2
Ownership
Shares Out.34.89M
Float32.28M
Insiders9.02%
Institutions14.00%
Short Interest
Short Ratio3.3d
Short % Float9.91%
Short % Out.9.11%
Shares Short3.13M
Short (prev mo.)2.71M
Technical
SMA 500.2948 (-9.3%)
SMA 2000.8293 (-67.7%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)1.08M
Avg Vol (10d)1.02M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—